Vanguard Capital Management Reports 5.08% Passive Stake In Dianthus Therapeutics
The 2,846,786-share position carries sole voting power over just 418,713 shares, and Vanguard says it holds no control motive.
Vanguard Capital Management now holds 2,846,786 shares of Dianthus Therapeutics, or 5.08% of the common stock, according to a passive ownership disclosure filed Friday. The filing lists September 30 as the event date.
Voting power covers a sliver
Vanguard has sole voting power over 418,713 of the shares and shared voting power over none. It holds sole dispositive power, meaning the authority to decide whether to sell, over all 2,846,786.
The filing describes the reporting person as an investment adviser. The stake counts shares Vanguard could acquire within 60 days.
The position covers shares held by Vanguard funds and by affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers and Vanguard Investments Australia. The filing says no single other person's interest in the securities exceeds 5%.
No bid for control
Vanguard certified that the shares were acquired and are held in the ordinary course of business. It said they were not bought to change or influence control of Dianthus, or in connection with any transaction with that purpose.
Dianthus, based in New York, is a clinical-stage biotechnology company developing treatments for severe autoimmune diseases. It has no approved products. Its lead candidate, claseprubart, is a self-injected antibody designed to block the complement protein C1s, and it is in three mid- to late-stage trials: generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
The company's market value was $4.6 billion in Friday trading, as of 11:32 a.m. ET.
Dianthus's second candidate, DNTH212, which targets two immune pathways, began an early-stage study in December 2025, according to the company's annual report.